Literature DB >> 8233504

Diuretic and diet effect on Menière's disease evaluated by the 1985 Committee on Hearing and Equilibrium guidelines.

P M Santos1, R A Hall, J M Snyder, L F Hughes, R A Dobie.   

Abstract

Fifty-four patients, diagnosed with Menière's disease and treated with diuretics and a low-salt diet, were evaluated retrospectively with the 1985 AAO/HNS Committee on Hearing and Equilibrium (CHE) guidelines for vertigo and hearing changes. The patient data base was also evaluated with other methods that helped determine the effectiveness of the 1985 AAO/HNS CHE guidelines. After 24 months of therapy, vertigo control was complete or substantial in 79% of the patients, limited or insignificant in 19%, and worse in 2% as evaluated by the CHE 1985 guidelines. Hearing improved in 35% of the patients, was unchanged in 29%, was worse in 22%, and could not be classified by CHE guidelines in 14%. Hearing was also evaluated by comparison of individual thresholds before medical therapy, and at 22 and 74 months after the start of medical therapy. We found a stabilization of low- and mid-threshold frequencies, with an average rate of hearing loss approximating 0 dB/yr with 74 months of followup. The results of this preliminary study suggest that diuretics and a low-salt diet may decrease the natural progression of sensorineural hearing loss in patients with Menière's disease. Compared with other methods of data analysis, the 1985 CHE guidelines lacked sensitivity to evaluate the hearing changes observed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8233504     DOI: 10.1177/019459989310900408

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  10 in total

1.  Vertigo in Older People.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

2.  Meniere's Syndrome.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

3.  Angular vestibulo-ocular reflex gains correlate with vertigo control after intratympanic gentamicin treatment for Meniere's disease.

Authors:  Frank R Lin; Americo A Migliaccio; Thomas Haslwanter; Lloyd B Minor; John P Carey
Journal:  Ann Otol Rhinol Laryngol       Date:  2005-10       Impact factor: 1.547

4.  Relationship between urinary angiotensinogen and salt sensitivity of blood pressure in patients with IgA nephropathy.

Authors:  Yoshio Konishi; Akira Nishiyama; Takashi Morikawa; Chizuko Kitabayashi; Mikiko Shibata; Masahiro Hamada; Masatsugu Kishida; Hirofumi Hitomi; Hideyasu Kiyomoto; Takenori Miyashita; Nozomu Mori; Maki Urushihara; Hiroyuki Kobori; Masahito Imanishi
Journal:  Hypertension       Date:  2011-06-13       Impact factor: 10.190

5.  Chiropractic management of a 40-year-old female patient with Ménière disease.

Authors:  Peter C Emary
Journal:  J Chiropr Med       Date:  2010-03

6.  Intratympanic dexamethasone application in Meniere's disease-Is it superior to conventional therapy?

Authors:  Gilbert Paragache; Naresh K Panda; Meena Ragunathan
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2005-01

Review 7.  Optimal management of Ménière's disease.

Authors:  Carol A Foster
Journal:  Ther Clin Risk Manag       Date:  2015-02-25       Impact factor: 2.423

8.  Changes of Vestibular Symptoms in Menière's Disease After Triple Semicircular Canal Occlusion: A Long-Term Follow-Up Study.

Authors:  Yumeng Jiang; Maoxiang Xu; Qingxiu Yao; Zhuangzhuang Li; Yaqin Wu; Zhengnong Chen; Dongzhen Yu; Haibo Shi; Shankai Yin
Journal:  Front Neurol       Date:  2022-02-04       Impact factor: 4.003

9.  Restriction of salt, caffeine and alcohol intake for the treatment of Ménière's disease or syndrome.

Authors:  Kiran Hussain; Louisa Murdin; Anne Gm Schilder
Journal:  Cochrane Database Syst Rev       Date:  2018-12-31

10.  Changes in the Results of the Subjective Visual Vertical Test After Endolymphatic Sac Drainage for Intractable Meniere's Disease.

Authors:  Tomoyuki Shiozaki; Yoshiro Wada; Taeko Ito; Toshiaki Yamanaka; Tadashi Kitahara
Journal:  J Int Adv Otol       Date:  2021-03       Impact factor: 1.316

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.